Upstream Bioprocessing Market - By Product (Bioreactors/Fermenters, Cell Culture Products, Filters), Usage Mode (Multi-use, Single-use), Mode (In-house, Outsourced), Application (Monoclonal Antibody, Vaccine Production), End-user – Global Forecast, 2024 – 2032

Upstream Bioprocessing Market Size

Upstream Bioprocessing Market size was valued at USD 9.5 billion in 2023 and is anticipated to grow at CAGR of 9.7% from 2024 and 2032. One of the major factors contributing to the growth is the increasing demand for biopharmaceuticals caused by high prevalence of chronic diseases.
 

Therefore, the efficient and scalable upstream processes are essential to meet the growing demand for biopharmaceuticals & advanced therapies and address unmet medical needs. Further, the technological advancements such as single-use bioreactors, high-throughput screening, and bioreactor design, enhance productivity, efficiency, and scalability contributes to the increasing adoption of upstream bioprocessing.
 

Upstream bioprocessing refers to the initial stages of biotechnological production processes involved in manufacturing biological products such as pharmaceuticals, enzymes, or biofuels. It encompasses various steps from the selection and cultivation of host organisms (such as bacteria, yeast, or mammalian cells) to the preparation of the growth medium and the actual cultivation of these organisms in bioreactors or fermenters.
 

Upstream Bioprocessing Market Trends

• Single-use bioprocessing systems offer numerous advantages over traditional stainless-steel systems. It offers several advantages including flexibility, reduced risk of cross-contamination, and faster turnaround time. Therefore, the growing acceptance of single-use bioreactors has resulted in development and technological advancement in bioreactors. For instance, in March 2021, Thermo Fisher Scientific launched large-scale single-use bioreactor systems with capacities beyond the standard limits. Thus, availability of such products/systems in the market is expected to spur the market growth.
   
• Further, the rising implementation of Process Analytical Technology (PAT) revolutionizes upstream bioprocessing by enabling real-time monitoring, analysis, and control of critical process parameters (CPPs) and quality attributes. PAT provides insights into bioprocesses, facilitating process optimization and improving product quality.
   

Therefore, the adoption of single-use bioprocessing systems and the implementation of PAT drive the growth in the market by enhancing efficiency, flexibility, and product quality.
 

Upstream Bioprocessing Market Analysis

Based on product, the market is segmented into bioreactors/ fermenters, cell culture products, filters, bioreactor accessories, bags & containers, and other products. The bioreactors/fermenters segment accounted for highest market share of 48.6% in 2023.
 

• Bioreactors/ fermenters are the primary vessels used for cell culture, which is the foundational process in upstream bioprocessing. These vessels provide a controlled environment for the growth and proliferation of cells or microorganisms, essential to produce biopharmaceuticals, enzymes, vaccines, and other bioproducts.
   
• Additionally, their scalability, flexibility and precise process control and monitoring collectively contributes to the growth of this segment.
   

Based on usage mode, the upstream bioprocessing market is classified into multi-use and single-use. The multi-use segment dominated the market and is anticipated to showcase growth at 9.1% CAGR over the coming years.
 

• Multi-use equipment are known for their durability and reliability, allowing for multiple cycles of operation without compromising performance, therefore makes them a preferred choice for many bioprocessing facilities.  
   
• Further, the versatility of multi-use equipment allows for its application in various stages of bioprocessing, from cell culture and fermentation to downstream processing. This adaptability enhances its value proposition for bioprocessing facilities seeking comprehensive solutions for their production needs.

Based on mode, the upstream bioprocessing market is categorized into in-house and outsourced. The in-house segment is expected to reach USD 11.8 billion by 2032.
 

• Companies benefit from in-house bioprocessing facilities, which offer increased operational flexibility and agility to adapt to evolving market dynamics and shifts in product demand.
   
• Moreover, these facilities empower companies to uphold rigorous quality control standards and adhere to regulatory requirements seamlessly throughout the entire manufacturing process. Due to these advantages over outsourced bioprocessing, the in-house segment is anticipated to experience growth.
   

Based on application, the upstream bioprocessing market is divided into monoclonal antibody production, vaccine production, cell & gene therapy production and other applications. The monoclonal antibody production segment accounted for USD 4.9 billion in 2023.
 

• The monoclonal antibodies (mAb) production segment held the highest market share in upstream bioprocessing due to its therapeutic importance, widespread clinical adoption, technological advancements, scalability, regulatory support, and diverse applications across various therapeutic areas.
   
• Additionally, the proven efficacy, safety, and market demand for mAb-based therapies, coupled with optimized production processes, have solidified mAb production in the biopharmaceutical industry, thereby fostering its dominance in upstream bioprocessing.
   

Based on end-user, the upstream bioprocessing market is classified into biopharmaceutical companies, CDMOs & CROs, and research & academic institutes. The biopharmaceutical companies segment is projected to grow at CAGR of 9.4% between 2024 and 2032.
 

• Biopharmaceutical companies are specialized in developing and manufacturing biological products, including monoclonal antibodies, vaccines, and recombinant proteins, thereby witnessing a surge in demand for their products. This demand necessitates upstream bioprocessing, leading to heightened adoption of such processes to maximize operational efficiency and product quality.
   
• Furthermore, vertical integration within biopharmaceutical companies enables seamless integration of upstream and downstream processing, optimizing overall manufacturing efficiency and reducing costs. These factors contribute to the dominance of biopharmaceutical companies in the market.

North America upstream bioprocessing market is estimated to reach over USD 9.5 billion by the end of forecast timeline.
 

• The increasing collaboration and partnerships with an aim of increasing awareness and education related to bioprocessing is expected to support the growth of this market. For instance, in 2018, Jefferson (Philadelphia University + Thomas Jefferson University) announced partnership with National Institute for Bioprocessing Research and Training (NIBRT) for creating Jefferson Institute for Bioprocessing, the first – and only – education and training institute for biopharmaceutical processing in North America.
   

Upstream Bioprocessing Market Share

The upstream bioprocessing industry is characterized by intense competition among key players, including biopharmaceutical companies, equipment manufacturers, contract manufacturing organizations (CMOs), and research institutions. Factors such as technological innovation, strategic partnerships, regulatory compliance, and geographic expansion drive competitiveness in this dynamic market.
 

Upstream Bioprocessing Market Companies

Key players operating in the upstream bioprocessing industry include:

• Applikon Biotechnology
• Boehringer Ingelheim GmbH
• CellGenix GmbH
• Corning, Inc.
• Danaher Corporation (Cytvia)
• Eppendorf AG
• Merck KGaA
• PBS Biotech, Inc.
• Sartorius AG
• Thermo Fisher Scientific Inc.
   

Upstream Bioprocessing Industry News:

• In April 2023, Cytiva launched X-platform bioreactors to simplify single-use upstream bioprocessing operations. This launch helped the company to drive revenue growth and differentiate itself from competitors by offering innovative solutions.
   
• In September 2023, Getinge launched AppliFlex ST GMP, a cutting-edge single-use bioreactor designed for clinical production of cell and gene therapies as well as mRNA production. This strategic initiative is expected to help the company to broaden its product portfolio and enter the untapped market.
   

The upstream bioprocessing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Bioreactors/Fermenters
• Cell culture products
• Filters
• Bioreactor accessories
• Bags & containers
• Other products

Market, By Usage Mode

• Multi-use
• Single-use

Market, By Mode

• In-house
• Outsourced

Market, By Application

• Monoclonal antibody production
• Vaccine production
• Cell and gene therapy production
• Other applications

Market, By End-user

• Biopharmaceutical companies
• CDMOs and CROs
• Research and academic institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa